NEW YORK, Aug. 14 (GenomeWeb News) - A unit of Germany's Merck KGaA has acquired closely held ProteoPlex, a St. Louis-based proteomics company.
Terms of the deal, sealed on Aug. 7 and disclosed on Aug. 12, call for ProteoPlex to become integrated within the subsidiary, EMD Biosciences. The companies would not divulge the cost of the acquisition to Merck.
ProteoPlex, which was spun out from Incyte Genomics in 2001, manufactures DNA chips and protein chips. Its first product, a 16-well antibody array, will be launched with Merck's help.
"The technology and competence of ProteoPlex are a perfect fit with our own proteomics R&D programs and will directly translate into new product offerings for our customers in the Life Sciences industry," Bernd Reckman, vice president and general manager of Merck KGaA's Life Science Products Division, said in a statement.
ProteoPlex employs eight people and will remain in St. Louis, according to David Smoller, president and CEO.